TET Systems and Novo Nordisk Sign License Agreement
News Nov 19, 2009
TET Systems Holding GmbH & Co. KG announced that TET Systems and Novo Nordisk A/S have signed a license agreement allowing the Hagedorn Research Institute (HRI), a research institute within Novo Nordisk A/S, the use of the Tet Technology for its internal research activities.
TET Systems was founded by Prof. Dr. H. Bujard and his colleagues. According to TET Systems, its technology is the most widely used method to control gene expression in higher organisms. 85% of the world's leading pharmaceutical companies license the Tet Technology for their internal R&D activities. The broad usage of the Tet Technology is demonstrated by more than 6,200 publications in peer-reviewed journals (June 2009).
“We are very glad that we can add the Hagedorn Research Institute as part of Novo Nordisk, one of the premier global pharmaceutical companies with European headquarters, to our growing list of licensees”, stated Dr. E. Bohnlein, CEO of TET Systems.
“This license agreement again shows that the Tet Technology provides a clear technological advantage to innovative biomedical research which translates into a strategic advantage for these pharmaceutical and biotech companies.”
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018